This narrative review aims to illustrate the notion that nonalcoholic steatohepatitis (NASH),
recently renamed metabolic dysfunction-associated steatohepatitis (MASH), is a systemic …

Liver cancer remains a challenge of global health, being the 4th leading cause of cancer
death worldwide. Hepatocellular carcinoma (HCC) is the most common type of primary liver …

Prognostication of compensated advanced chronic liver disease (cACLD) is of paramount
importance for the physician-and-patient communication and for rational clinical decisions …

Introduction Accurate and reliable diagnosis and monitoring of hepatic fibrosis is
increasingly important given the variable natural history in chronic liver disease (CLD) and …

Metabolic dysfunction–associated steatotic liver disease (MASLD) is a prevalent condition
with a broad spectrum defined by liver biopsy. This gold standard method evaluates three …

Improved understanding of the natural history of metabolic dysfunction-associated steatotic
liver disease (MASLD) is key to accurate prognostication of disease and ascertainment of …

Background/Aims New prognostic markers are needed to identify patients with
hepatocellular carcinoma (HCC) who carry a worse prognosis. Ultra-low-pass whole …

Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most
common cause of chronic liver disease. Its prevalence is increasing with the epidemic of …

Obesity and associated insulin resistance induce a chronic metabo-inflammatory state that
lead to injury and dysfunction of multiple organs resulting in a cluster of noncommunicable …

In managing metabolic dysfunction-associated steatotic liver disease, which affects over
30% of the general population, effective noninvasive biomarkers for assessing disease …